Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Nick Henriquez

Knowledge Exchange Coordinator Office of the Vice-Provost (Enterprise)

Nick Henriquez

T: 020 7679 7525
E: n.henriquez@ucl.ac.uk

Nick joined the Office of the Vice-Provost (Enterprise) as Knowledge Exchange Coordinator in November 2012. His primary role is to facilitate the distribution of UCL’s Knowledge Exchange and Enterprise funding to the academic Departments, and monitoring the progress of funded projects. His responsibilities include drafting calls, ensuring applications are in order, collating panel reviews, facilitating application review meetings and following up on the progress of successful applications.

Nick has a PhD in Immunology and has worked for 20 years in the areas of cancer and inflammatory diseases in Birmingham, Leadd BV (a small biopharmaceutical company), Leiden University Medical Centre and in the Department of Neurodegenerative Diseases at the UCL Inst. of Neurology.